Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer
Our study shows that CTCs provide key information that would have been missed by ctDNA monitoring alone and extends CTC and cfDNA genomic profiling to patients with a broad range of CTC counts for blood-based monitoring of HER2 status and other clinically actionable targets for informing treatment decisions in metastatic disease.
Authors
- Karen Page (ORCID: https://orcid.org/0000-0003-0440-9244)
- Georgios Nteliopoulos (ORCID: https://orcid.org/0000-0002-9764-4288)
- Gurdeep Matharu Lall
- Rebecca C. Allsopp (ORCID: https://orcid.org/0000-0003-4887-8632)
- Marc Wadsley (ORCID: https://orcid.org/0000-0002-7014-2595)
- Evie Wren (ORCID: https://orcid.org/0009-0008-3361-0274)
- R. Charles Coombes (ORCID: https://orcid.org/0000-0002-4811-1100)
- Emmanuel Acheampong (ORCID: https://orcid.org/0000-0002-5338-3258)
- Jacqui Shaw (ORCID: https://orcid.org/0000-0003-4227-503X)
- Kelly Gleason
- Shradha Bhagani (ORCID: https://orcid.org/0000-0001-7251-2249)
Institutions
- University of Leicester (GB)
- Breast Cancer Now (GB)
- Leicester Royal Infirmary (GB)
- Hammersmith Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s12885-025-15187-5
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hope Against Cancer
- Cancer Research UK
- National Institute for Health and Care Research
- University of Leicester
- Imperial College London
- NIHR Leicester Biomedical Research Centre